What Is AIDS Wasting Syndrome and How Is It Treated?

AIDS wasting syndrome is an involuntary loss of more than 10 percent of body weight, combined with chronic diarrhea or weakness and fever, in a person living with HIV. It was once among the most visible and feared complications of advanced HIV disease, and while modern antiretroviral therapy has dramatically reduced catastrophic weight loss, wasting has not disappeared. Large cohort studies find that roughly 12 to 18 percent of people with HIV still meet criteria for wasting or clinically low weight, even in the current treatment era. Understanding why wasting persists, what drives it biologically, and how it can be managed requires looking well beyond the virus itself.

How Wasting Is Defined and Why the Definition Matters

The CDC originally added HIV-associated wasting as an AIDS-defining condition in 1987, recognizing the severe, often fatal weight loss that accompanied advanced infection. The clinical threshold has remained the same: unintentional loss of more than 10 percent of baseline body weight, with either chronic diarrhea lasting at least 30 days or chronic weakness and documented fever, in the absence of any illness other than HIV that could explain the weight loss. That 10 percent cutoff might sound like a lot, but for someone who weighed 150 pounds, it amounts to losing just 15 pounds, which can happen gradually enough to go unnoticed until functional capacity drops sharply.

What makes wasting particularly dangerous is that the weight being lost is not mainly fat. It is lean tissue, the muscle and organ mass your body depends on for strength, immune function, and survival. Loss of this metabolically active lean tissue has been linked to faster disease progression, higher mortality, and significant impairment of strength and day-to-day function.¹ A person can lose a dangerous amount of lean mass without the scale showing dramatic overall weight loss, particularly if fat mass increases at the same time. This subtlety is one reason wasting still gets missed.

How Common Is Wasting in the Modern Treatment Era

Many clinicians assumed that effective antiretroviral therapy would eliminate wasting. It has not. In a large U.S. cohort study covering the years 2016 to 2020, the period prevalence of HIV-associated wasting or low weight was about 12 percent, identical to the rate seen in the period just before modern combination therapy became widespread.² Among those without a prior history of wasting, about 7 percent developed new-onset wasting or low weight during that period, with a median onset roughly nine months from baseline. A separate insurance-claims analysis found cumulative prevalence figures closer to 18 percent, regardless of whether patients were using antiretroviral therapy.³ The persistence of wasting across these different data sources, and across calendar years, makes it clear that viral suppression alone does not eliminate the problem.

What Drives Wasting at a Biological Level

Wasting in HIV is not simply the result of eating less. It arises from a tangle of overlapping problems: chronic inflammation, hormonal disruption, gut damage, and opportunistic infections, often operating simultaneously. The relative contribution of each factor varies from person to person, which is part of why treatment can be so difficult.

Chronic Inflammation and Cytokine-Driven Muscle Loss

Even when the virus is well controlled by medication, many people with HIV live with low-grade chronic inflammation. The immune system continues to churn out signaling molecules called cytokines, and certain ones, particularly tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), directly promote the breakdown of lean tissue. In one study of men on effective antiretroviral therapy who were not losing dramatic amounts of weight, researchers found that production of TNF-alpha and IL-1 beta by immune cells predicted loss of lean body mass over time. The same cytokines also drove up resting energy expenditure, meaning the body burned more calories at rest than it should, which about 18 percent of the study participants experienced regardless of weight change.⁴ This kind of wasting, a slow erosion of muscle mass driven by inflammation rather than starvation, can be invisible on a standard bathroom scale.

The broader picture is that multiple alterations in anabolic hormones, energy intake, energy expenditure, and cytokine production all converge to push the body toward catabolism, the breakdown of its own tissues for fuel.⁵ This mechanism resembles cachexia in cancer or severe chronic illness, which is why simply eating more calories does not reliably reverse the problem.

Hormonal Disruptions

HIV and some of its treatments can suppress the body’s production of testosterone and other anabolic hormones. In men with AIDS wasting who also had low testosterone, free testosterone levels were strongly correlated with total body potassium (a marker of lean mass) and with muscle mass, while total testosterone correlated with exercise capacity on functional tests like the six-minute walk.⁶ The same study found evidence of growth hormone resistance, a state where the body produces growth hormone but the tissues fail to respond to it normally. In wasting syndrome, growth hormone levels may actually be elevated while IGF-1, the downstream signal that normally stimulates tissue growth, remains low.⁷ The result is a double hit: not enough testosterone to build muscle, and a growth hormone system that is active but ineffective.

Gut Damage and Malabsorption

HIV has a particular affinity for the immune cells lining the gut, and the resulting damage is sometimes called HIV enteropathy. The virus disrupts the intestinal barrier, reduces the absorptive surface area, and allows bacteria and bacterial products to leak into the bloodstream, fueling the chronic inflammation described above. In experimental models, this damage leads to functional immaturity of the cells lining the intestine and impaired nutrient absorption.⁸ On top of this, opportunistic infections of the gastrointestinal tract, such as cryptosporidiosis or cytomegalovirus colitis, can cause severe diarrhea and further worsen malabsorption.⁹ For some patients, the gut is simply too damaged to extract enough nutrition from food, regardless of how much they eat.

Appetite Disruption and Its Neuroendocrine Roots

People with wasting frequently report profound loss of appetite, and this is not just a side effect of feeling sick. Research has found that people with AIDS-related wasting have significantly higher blood levels of cholecystokinin (a hormone that signals fullness after eating) and lower levels of beta-endorphin (which normally helps stimulate appetite), compared to well-nourished people with AIDS or to uninfected controls. At the same time, inflammatory markers including TNF-alpha and its receptors were elevated in the wasting group.¹⁰ In other words, the appetite control system itself gets rewired by chronic inflammation and hormonal shifts, creating a biological drive to eat less precisely when the body needs more fuel. This helps explain why telling a person with wasting to “just eat more” often fails spectacularly.

Treatment Approaches

Managing wasting effectively usually requires attacking the problem from multiple angles simultaneously: controlling the virus, addressing inflammation, restoring hormones when deficient, boosting nutritional intake, and rebuilding muscle through exercise.

Appetite Stimulants and Hormonal Therapies

Dronabinol, a synthetic form of the active compound in cannabis, is approved for treating anorexia and weight loss in adults with HIV. It acts on appetite and nausea centers in the brain, helping patients eat more and keep food down.¹¹ Long-term data show that appetite improvements tend to persist, and patients on dronabinol maintained relatively stable weight for at least seven months.¹² However, the weight gained with dronabinol alone tends to be modest. In one head-to-head trial comparing dronabinol with megestrol acetate (a synthetic hormone), patients on megestrol gained substantially more weight over 12 weeks, while those on dronabinol alone actually lost a small amount.¹³ The catch with megestrol is that much of the weight gained is fat rather than lean tissue, which does not solve the core problem of muscle loss.

Recombinant human growth hormone (rhGH) takes a different approach by directly targeting lean tissue. In a randomized trial, patients receiving growth hormone gained an average of about 3 kg of lean body mass over 12 weeks while losing roughly 1.7 kg of fat, a favorable shift in body composition that placebo patients did not experience.¹⁴ Across multiple controlled studies, rhGH has been associated with improvements in physical endurance and quality of life as well.¹⁵ Growth hormone therapy is expensive and can cause side effects like joint pain and fluid retention, so it tends to be reserved for more severe cases.

Nutritional Support

Targeted nutrition interventions go beyond generic advice to eat more. Customized dietary programs that match calorie and protein goals to an individual’s needs have been shown to reverse unintentional weight loss over periods of 5 to 15 months.¹⁶ One particularly promising area involves supplementation with a combination of beta-hydroxy beta-methylbutyrate (HMB), glutamine, and arginine. In a controlled study, patients taking this mixture gained an average of 3 kg over eight weeks, and the gain was predominantly lean mass, while the placebo group actually lost lean tissue.¹⁷ HMB is a metabolite of the amino acid leucine and is thought to reduce protein breakdown in muscle cells, which makes it a useful complement to strategies that increase protein intake.

Progressive Resistance Exercise

Strength training is one of the most consistently effective interventions for wasting, and one that carries very few downsides. Research has demonstrated that progressive resistance exercise can significantly increase lean body mass in patients with wasting without increasing circulating HIV levels.¹⁸ In a controlled trial of men with AIDS wasting who had normal testosterone levels, those randomized to resistance training gained significantly more arm and leg muscle cross-sectional area than those who did not train.¹⁹ When testosterone replacement was combined with resistance training, both muscle mass and muscle quality improved, with computed tomography scans showing denser, less fatty muscle tissue after the intervention.²⁰ Unlike some pharmacological treatments that can worsen metabolic profiles, exercise consistently produces positive changes across multiple health measures.

How Wasting Affects Quality of Life

The toll of wasting extends far beyond the number on the scale. Qualitative research with people experiencing HIV-related wasting has documented a profound negative impact on quality of life, driven primarily by crushing fatigue, visible changes in appearance, and persistent gastrointestinal symptoms. These effects ripple into physical, psychological, social, and sexual functioning.²¹ In an era when HIV is increasingly manageable as a chronic condition, visible wasting can mark someone as seriously ill, carrying social stigma that compounds the physical suffering.

These effects are not just temporary. Data from the Multicenter AIDS Cohort Study show that a history of HIV wasting is associated with persistently lower grip strength and poorer physical quality of life compared to people with HIV who never experienced wasting, and poorer physical quality of life compared to HIV-negative men, even years after the acute wasting episode has resolved.²² In other words, wasting leaves a lasting scar on the body’s functional capacity, making it all the more important to catch and treat it early rather than waiting for dramatic weight loss to occur.

When Medications Themselves Contribute to Muscle Damage

Some older antiretroviral drugs, particularly thymidine analogues like zidovudine (AZT) and stavudine (d4T), have been associated with direct toxicity to muscle tissue. Laboratory research has shown that AZT can interfere with the normal cellular recycling process in muscle cells, causing damaged mitochondria to accumulate. These dysfunctional mitochondria generate excessive reactive oxygen species, essentially producing internal oxidative stress that compromises cell survival.²³ While these older drugs are now rarely used in high-income countries, they remain part of treatment regimens in some resource-limited settings.

Interestingly, a study examining skeletal muscle biopsies from people on current antiretroviral regimens found that prior exposure to these older drugs did not clearly predict higher levels of mitochondrial dysfunction in muscle fibers years later.²⁴ This suggests that switching away from toxic drugs may allow some degree of recovery, though the picture is complicated by the fact that HIV infection itself and aging both contribute independently to mitochondrial problems in muscle.

Wasting, Sarcopenia, and Aging With HIV

As people with HIV live longer thanks to effective treatment, a new concern has emerged at the intersection of wasting and aging. Sarcopenia, the gradual loss of muscle mass and strength that occurs with aging in everyone, appears to be accelerated in people living with HIV. Data from the Multicenter AIDS Cohort Study suggest that both grip strength and walking speed decline faster after the ages of 50 to 60 in men with HIV compared to uninfected men, even after accounting for viral suppression and other HIV-related factors.²⁵ For someone who already lost lean tissue to wasting earlier in their disease course, this accelerated age-related decline starts from a lower baseline, compounding the functional deficit.

Frailty, a clinical state characterized by weakness, slowness, exhaustion, and vulnerability to falls and hospitalization, affects a meaningful proportion of older adults with HIV. The relationship between sarcopenia and frailty in this population appears to be bidirectional: muscle loss contributes to frailty, and the reduced activity and poor nutrition that come with frailty accelerate further muscle loss.²⁶ For clinicians managing HIV in older patients, this means that body composition monitoring and proactive exercise programs are becoming as important as viral load counts. The era of wasting as a dramatic, visible emergency may be fading, but the quieter erosion of muscle and function continues to shape outcomes for people aging with HIV.